These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8464176)

  • 21. Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine-treated rat liver.
    Nakai T; Katagiri K; Hoshino M; Hayakawa T; Ohiwa T
    Biochem J; 1992 Dec; 288 ( Pt 2)(Pt 2):613-7. PubMed ID: 1361125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letter: serum vitamin D levels in primary biliary cirrhosis.
    Bruns T; Kittler C; Stengel S; Trivedi PJ; Stallmach A
    Aliment Pharmacol Ther; 2015 Sep; 42(5):633-4. PubMed ID: 26238585
    [No Abstract]   [Full Text] [Related]  

  • 23. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 24. Tauroursodeoxycholic acid and 4-phenyl butyric acid alleviate endoplasmic reticulum stress and improve prognosis of donation after cardiac death liver transplantation in rats.
    Lu H; Lu L; Xu ZC; Lu YJ; Zhao B; Zhuang L; Hao BB; Zhang F
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):586-93. PubMed ID: 25475860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter: serum vitamin D levels in primary biliary cirrhosis--authors' reply.
    Guo G; Shi Y; Han Y; Zhou X
    Aliment Pharmacol Ther; 2015 Sep; 42(5):635. PubMed ID: 26238586
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-cholestatic activity of HD-03, a herbal formulation in thioacetamide (TAA)-induced experimental cholestasis.
    Mitra SK; Venkataranganna MV; Gopumadhavan S; Sundaram R
    Indian J Exp Biol; 1999 Apr; 37(4):409-10. PubMed ID: 10641180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.
    Crosignani A; Battezzati PM; Setchell KD; Invernizzi P; Covini G; Zuin M; Podda M
    Dig Dis Sci; 1996 Apr; 41(4):809-15. PubMed ID: 8674405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis.
    Sánchez Pozzi EJ; Crocenzi FA; Pellegrino JM; Catania VA; Luquita MG; Roma MG; Rodríguez Garay EA; Mottino AD
    J Pharmacol Exp Ther; 2003 Jul; 306(1):279-86. PubMed ID: 12663690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat.
    Rivard AL; Steer CJ; Kren BT; Rodrigues CM; Castro RE; Bianco RW; Low WC
    Am J Chin Med; 2007; 35(2):279-95. PubMed ID: 17436368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophils and primary biliary cirrhosis-stoking the fire?
    Neuberger J
    Hepatology; 1999 Jul; 30(1):335-7. PubMed ID: 10385676
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans.
    Loria P; Bozzoli M; Concari M; Guicciardi ME; Carubbi F; Bertolotti M; Piani D; Nistri A; Angelico M; Romani M; Carulli N
    Hepatology; 1997 Jun; 25(6):1306-14. PubMed ID: 9185744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estradiol-17 beta-D-glucuronide (E-17G) cholestasis in perfused rat liver: fate of E-17G and choleretic responses to bile salts.
    Utili R; Tripodi MF; Adinolfi LE; Gaeta GB; Abernathy CO; Zimmerman HJ
    Hepatology; 1990 May; 11(5):735-42. PubMed ID: 2347547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization.
    Ono T; Imai K; Kohno H; Uchida M; Takemoto Y; Dhar DK; Nagasue N
    Dig Dis Sci; 1998 Oct; 43(10):2201-10. PubMed ID: 9790455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease.
    Heubi JE; Wiechmann DA; Creutzinger V; Setchell KD; Squires R; Couser R; Rhodes P
    J Pediatr; 2002 Aug; 141(2):237-42. PubMed ID: 12183720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bile salt independent flow during bile salt-induced choleresis and cholestasis in the rat: role of biliary thiol secretion.
    Bouchard G; Tuchweber B; Yousef IM
    Liver; 2000 Feb; 20(1):27-37. PubMed ID: 10726958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Primary biliary cirrhosis and ursodeoxycholic acid therapy].
    Makino I
    Nihon Naika Gakkai Zasshi; 1996 Mar; 85(3):399-403. PubMed ID: 8691003
    [No Abstract]   [Full Text] [Related]  

  • 39. [Primary biliary cirrhosis: therapeutic options].
    Abenavoli L
    Recenti Prog Med; 2009 Sep; 100(9):417-23. PubMed ID: 19886235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose.
    Gaspar JM; Martins A; Cruz R; Rodrigues CM; Ambrósio AF; Santiago AR
    Neuroscience; 2013 Dec; 253():380-8. PubMed ID: 24012838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.